BRPI0408500A - Type 1 diabetes treatment with pde5 inhibitors - Google Patents

Type 1 diabetes treatment with pde5 inhibitors

Info

Publication number
BRPI0408500A
BRPI0408500A BRPI0408500-0A BRPI0408500A BRPI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A BR PI0408500 A BRPI0408500 A BR PI0408500A
Authority
BR
Brazil
Prior art keywords
type
diabetes
pde5 inhibitors
diabetes treatment
treatment
Prior art date
Application number
BRPI0408500-0A
Other languages
Portuguese (pt)
Inventor
Gillian Munro Burgess
Earl Michael Gibbs
Christopher Peter Wayman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0408500A publication Critical patent/BRPI0408500A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"TRATAMENTO DO DIABETES DO TIPO 1 COM INIBIDORES DE PDE5". O uso de um inibidor de PDE5 sem atividade substancial de inibição de PDE2, ou um sal farmaceuticamente aceitável do mesmo na preparação de um medicamento para o tratamento do Diabetes do Tipo 1. Um método para tratar o diabetes do tipo 1 em um indivíduo sofrendo de diabetes do Tipo 1, cujo método compreende a administração ao referido indivíduo de uma quantidade eficaz de um inibidor de PDE5 sem atividade substancial de inibição de PDE2,ou de um sal farmaceuticamente aceitável do mesmo."TYPE 1 DIABETES TREATMENT WITH PDE5 INHIBITORS". The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method for treating Type 1 diabetes in an individual suffering from Type 1 diabetes, which method comprises administering to said subject an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.

BRPI0408500-0A 2003-03-17 2004-03-04 Type 1 diabetes treatment with pde5 inhibitors BRPI0408500A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17
PCT/IB2004/000696 WO2004082667A1 (en) 2003-03-17 2004-03-04 Treatment of type 1 diabetes with pde5 inhibitors

Publications (1)

Publication Number Publication Date
BRPI0408500A true BRPI0408500A (en) 2006-03-07

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408500-0A BRPI0408500A (en) 2003-03-17 2004-03-04 Type 1 diabetes treatment with pde5 inhibitors

Country Status (7)

Country Link
EP (1) EP1605925A1 (en)
JP (1) JP2006520777A (en)
BR (1) BRPI0408500A (en)
CA (1) CA2519357A1 (en)
MX (1) MXPA05009242A (en)
TW (1) TW200503666A (en)
WO (1) WO2004082667A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563693C (en) * 2004-04-19 2010-07-06 Loma Linda University Composition and method of decreasing renal ischemic damage
EP1909793A2 (en) * 2005-07-15 2008-04-16 Proxomed Medizintechnik GmbH Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors
JP2009515816A (en) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド Novel formulations comprising fenofibrate and statins and related methods of treatment
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
PT2152663E (en) 2007-06-04 2014-06-03 Univ Ben Gurion Tri-aryl compounds and compositions comprising the same
CN108452311A (en) * 2012-11-13 2018-08-28 纽斯尔特科学公司 Composition for enhancing energetic supersession and method
CA3178035A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
MX2017016930A (en) * 2017-12-19 2019-06-20 Malesil Research & Tech Llc Method of treatment of diabetic foot ulcers.
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346937A1 (en) * 1998-10-15 2000-04-27 Per O. G. Arkhammar Specific therapeutic interventions obtained by interference with redistribution and/or targeting
KR100353014B1 (en) * 1998-11-11 2002-09-18 동아제약 주식회사 Pyrazolopyrimidinone derivatives for the treatment of impotence
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
IL153426A0 (en) * 2000-06-30 2003-07-06 Pfizer Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
KR20030023747A (en) * 2000-08-11 2003-03-19 화이자 인코포레이티드 Treatment of the insulin resistance syndrome
AU2002226633A1 (en) * 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
JP2004527510A (en) * 2001-03-16 2004-09-09 ファイザー インコーポレイテッド Pyrazolo [4,3-d] pyrimidinone compounds as CGMPDE inhibitors
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Also Published As

Publication number Publication date
TW200503666A (en) 2005-02-01
EP1605925A1 (en) 2005-12-21
WO2004082667A1 (en) 2004-09-30
JP2006520777A (en) 2006-09-14
MXPA05009242A (en) 2006-04-18
CA2519357A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
AR044007A1 (en) METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
BRPI0418029A (en) cd40 antibody formulation and methods
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BR0316305A (en) A compound or a pharmaceutically acceptable salt thereof, methods for treating pain in an animal, for stimulating opioid receptor function in a cell, for preparing a composition, and for treating diarrhea in an animal, composition, and kit.
TW200639159A (en) Treatment of pain
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
BRPI0413974A (en) combination, method of treating cancer in a warm-blooded animal, pharmaceutical composition, and, use of a combination
EA200700407A1 (en) HINAZOLIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA
MX2009004017A (en) The uses of the carboxy-amido-triazole compounds and salts thereof.
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
BRPI0514390A (en) the enantiomer of a compound or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, use thereof, methods for treating cancer, to produce an eg5 inhibitory effect on a warm-blooded animal and to treat disease, and, composition. pharmaceutical
CA2632207C (en) Use of calcitonin for the treatment of ra
BR0316458A (en) Compound, pharmaceutical composition, method of treating or preventing disease, method for enhancing cognition in a healthy patient, and use of a compound
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
NO20024646D0 (en) Combination therapies with vasculature-damaging activity
BRPI0408500A (en) Type 1 diabetes treatment with pde5 inhibitors
BRPI0508333A (en) use of a vitamin d compound, method of preventing and / or treating interstitial cystitis, pharmaceutical formulation, vitamin d compound, and kit
BR0307410A (en) Use of pde5 inhibitors in the treatment of healing and fibrosis
TW200742580A (en) Methods for treating nephrolithiasis
BRPI0519036A2 (en) method for treating a patient with a neurodegenerative disease; pharmaceutical composition for treating a neurodegenerative disease; and use of a 5-ht6 agonist or 5-ht6 agonist
DK1656131T3 (en) Use of betaine to treat claudicatio intermittens
EA200900269A1 (en) DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
UY30557A1 (en) TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS
BR112015012497A2 (en) pharmaceutical combinations

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired